Belvedere M, Plüss H J
Hämatologisch-onkologische Abteilung der Universitäts-Kinderklinik Zürich.
Helv Paediatr Acta. 1989 Jun;43(5-6):423-31.
Between 1967 and 1987 58 children with the diagnosis of neuroblastoma or ganglioneuroblastoma, all under 10 years of age, were admitted to the University Children's Hospital of Zurich for treatment. According to Evan's classification, 8 (14%) patients had stage I disease, 5 (9%) stage II, 6 (10%) stage III, 26 (45%) stage IV, and 13 (22%) stage IV-S. The 2-year survival rate of 46 patients with adequate follow-up was 6/6 (100%) for stage I, 4/4 (100%) for stage II, 5/6 (83%) for stage III, 6/23 (26%) for stage IV, and 7/7 (100%) for stage IV-S. The excellent results in stage IV-S patients confirm the active but cautious treatment policy. Analysis of catecholamine metabolites in 24-hour urine collections proved to be a reliable method to evaluate the further course: all 21 children who showed complete normalization of metabolite levels during therapy, survived.
1967年至1987年间,苏黎世大学儿童医院收治了58名诊断为神经母细胞瘤或神经节神经母细胞瘤的患儿,年龄均在10岁以下。根据埃文斯分类法,8名(14%)患者为I期疾病,5名(9%)为II期,6名(10%)为III期,26名(45%)为IV期,13名(22%)为IV-S期。46名有充分随访资料的患者的2年生存率为:I期6/6(100%),II期4/4(100%),III期5/6(83%),IV期6/23(26%),IV-S期7/7(100%)。IV-S期患者的良好结果证实了积极但谨慎的治疗策略。24小时尿儿茶酚胺代谢产物分析被证明是评估后续病程的可靠方法:治疗期间代谢产物水平完全恢复正常的21名儿童全部存活。